Eurofarma announces the winning projects in the Synapsis program
Published in: March 7, 2018
and updated in: November 4, 2021
Listen to the text
Stop the audio
São Paulo, March 2018 – Eurofarma, a multinational pharmaceutical company with 100% Brazilian capital, is announcing the 12 startups selected in the Synapsis program, in partnership with Endeavor. The selection by the examining board was held on Wednesday, March 7, after 4 months of registrations and more than 300 projects submitted. The chosen ones were the scale-ups more connected with the future and willing to be part of the transformation of the health sector in the areas: Relationship with Interest Groups, Efficiency Gain, Market Intelligence and People Management.
Starting now, the selected companies will receive mentoring from the Endeavor network and access to entrepreneurs at a similar development stage. They will also have access to Eurofarma’s network of relationships, which includes over 4,000 suppliers, 1,500 active customers (B2B), and over 600,000 medical contacts per month, covering all specialties.
According to Maria Del Pilar Muñoz, Vice President of Sustainability and New Business, the entrepreneurs’ engagement with the Synapsis project shows the importance that the investment in open research represents for Eurofarma: “We are happy with the repercussion and commitment that Synapsis received from companies across the country. One of Eurofarma’s missions is to invest in Innovation, and we believe that startups have a key role to play in bringing the domestic industry closer to open innovation.
Learn more about selected companies, in alphabetical order:
About the Eurofarma Group
The Eurofarma Group is the first Brazilian pharmaceutical multinational with 100% domestic capital. Acknowledged by the medical community and society for promoting access to health and quality of life with fair treatment, quality and innovation, it is present in 20 countries. In addition to Brazil, it has its own operations in Argentina, Bolivia, Chile, Colombia, Peru, Uruguay, Ecuador, Venezuela, Paraguay, and Central America (Guatemala, Belize, Costa Rica, El Salvador, Honduras, Nicaragua, Panama, Dominican Republic), as well as offices in Mexico and Mozambique for the submission of dossiers.
With 46 years of existence, it has been a prominent company in the segments in which it operates: Medical Prescription and OTC Drugs, Generic Drugs, Hospital Products, Tenders, Oncology, Veterinary Medicine, and Services to Third Parties. Its portfolio includes 335 products and, as of 2017, over 320 million units of drugs were produced. In 2017, the Group reached revenues of R$3.7 billion, 11% higher than the previous year, with Brazil accounting for 87.2% of this amount.
Eurofarma invests 5.7% of its net sales in Research & Development, being the Brazilian pharmaceutical company that invests the most in this area. In 2017, R$179 million were invested in R&D.
Considered one of the best companies to work for, according to the Great Place to Work (GPTW) rankings, the Eurofarma Group has roughly 6,300 employees and one of the largest sales and medical advertisement forces in Latin America.
For more information, please visit www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram: @eurofarma_br
About Endeavor
Endeavor is one of the leading non-profit organizations supporting entrepreneurs in the world. It acts in the mobilization of public and private organizations and in the sharing of practical knowledge and examples of high impact entrepreneurs to strengthen the entrepreneurial culture in the country.
In Brazil since 2000, it has already helped generate almost R $ 4 billion in revenues annually and more than 20,000 direct jobs through programs to support entrepreneurs; and to train more than 10 million Brazilians with on-site and distance educational programs.
MEDIA RELATIONS:
Eurofarma Laboratórios
Juliana Guerra - Tel. (11) 5090-8600 r.8369 - juliana@gaspar.com.br
Guilherme Gaspar – Tel. (11) 3065-3045 – guilherme@gaspar.com.br
Endeavor – Barbara Freiris | (11) 4504-2477| barbara.freiris@endeavor.org.br
Starting now, the selected companies will receive mentoring from the Endeavor network and access to entrepreneurs at a similar development stage. They will also have access to Eurofarma’s network of relationships, which includes over 4,000 suppliers, 1,500 active customers (B2B), and over 600,000 medical contacts per month, covering all specialties.
According to Maria Del Pilar Muñoz, Vice President of Sustainability and New Business, the entrepreneurs’ engagement with the Synapsis project shows the importance that the investment in open research represents for Eurofarma: “We are happy with the repercussion and commitment that Synapsis received from companies across the country. One of Eurofarma’s missions is to invest in Innovation, and we believe that startups have a key role to play in bringing the domestic industry closer to open innovation.
Learn more about selected companies, in alphabetical order:
| BirminD | www.birmind.com.br | Industrial optimization software, capable of reducing input waste in processes, through the evaluation of equipment. |
| Fofuuu | www.fofuuu.com | A platform of exercises and speech therapy treatment for children, with the possibility of customization by the professional, both for the Web and for mobile devices. |
| Geofusion | www.geofusion.com.br | A technology company specialized in geographic market intelligence, with a mapping, analytics and consulting platform. |
| GN Tech | www.gntech.med.br | A DNA analysis solution aimed at patients with psychiatric diseases, allowing the customization of medical prescriptions, with greater precision to patients. |
| Gupy | www.gupy.com.br | A management platform for recruitment and selection processes, based on artificial intelligence and machine learning. |
| Lean Survey | http://leansurvey.com.br | A smartphone app that turns the device into an opinion survey platform. Users receive training and recruitment. |
| Looqbox | www.looqbox.com | A data search tool for companies using machine learning, streamlining the location of information. |
| MZ Tecnologia | www.qualitystorm.com.br | Real-time quality management software for production lines and all processes that require validation. |
| Nexo Data | https://nexodata.com.br | An electronic drug prescription module to replace paper prescriptions with their digital versions. Agreements signed with over 30,000 pharmacies. |
| Plataforma Verde | www.plataformaverde.com.br | A software program for solid waste management, control of disposal processes, financial flow and legislation. |
| Prontmed | www.prontmed.com | A patient clinical data management platform, with electronic medical records for hospitals and laboratories. |
| Remédio Certo | www.remediocerto.com | A system that monitors the use of drugs for continuous use by chronic patients and promotes the recurring delivery of the drug at home, through a network of partner drugstores. |
About the Eurofarma Group
The Eurofarma Group is the first Brazilian pharmaceutical multinational with 100% domestic capital. Acknowledged by the medical community and society for promoting access to health and quality of life with fair treatment, quality and innovation, it is present in 20 countries. In addition to Brazil, it has its own operations in Argentina, Bolivia, Chile, Colombia, Peru, Uruguay, Ecuador, Venezuela, Paraguay, and Central America (Guatemala, Belize, Costa Rica, El Salvador, Honduras, Nicaragua, Panama, Dominican Republic), as well as offices in Mexico and Mozambique for the submission of dossiers.
With 46 years of existence, it has been a prominent company in the segments in which it operates: Medical Prescription and OTC Drugs, Generic Drugs, Hospital Products, Tenders, Oncology, Veterinary Medicine, and Services to Third Parties. Its portfolio includes 335 products and, as of 2017, over 320 million units of drugs were produced. In 2017, the Group reached revenues of R$3.7 billion, 11% higher than the previous year, with Brazil accounting for 87.2% of this amount.
Eurofarma invests 5.7% of its net sales in Research & Development, being the Brazilian pharmaceutical company that invests the most in this area. In 2017, R$179 million were invested in R&D.
Considered one of the best companies to work for, according to the Great Place to Work (GPTW) rankings, the Eurofarma Group has roughly 6,300 employees and one of the largest sales and medical advertisement forces in Latin America.
For more information, please visit www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram: @eurofarma_br
About Endeavor
Endeavor is one of the leading non-profit organizations supporting entrepreneurs in the world. It acts in the mobilization of public and private organizations and in the sharing of practical knowledge and examples of high impact entrepreneurs to strengthen the entrepreneurial culture in the country.
In Brazil since 2000, it has already helped generate almost R $ 4 billion in revenues annually and more than 20,000 direct jobs through programs to support entrepreneurs; and to train more than 10 million Brazilians with on-site and distance educational programs.
MEDIA RELATIONS:
Eurofarma Laboratórios
Juliana Guerra - Tel. (11) 5090-8600 r.8369 - juliana@gaspar.com.br
Guilherme Gaspar – Tel. (11) 3065-3045 – guilherme@gaspar.com.br
Endeavor – Barbara Freiris | (11) 4504-2477| barbara.freiris@endeavor.org.br